NSAIDs in paediatrics: caution with varicella!
L Durand1,2, P Sachs3, C Lemaitre4
1Pharmacie, Hôpital Robert-Debré, APHP, 48 bd Sérurier, 75019, Paris, France.
International Journal of Clinical Pharmacy
|August 23, 2015
Summary
Non-steroidal anti-inflammatory drugs (NSAIDs) may worsen bacterial infections in children with varicella (chickenpox). Caution is advised when prescribing NSAIDs to pediatric patients due to potential risks.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Varicella (chickenpox) is a common childhood illness.
- Concerns exist regarding anti-inflammatory drugs potentially exacerbating bacterial infections in varicella patients.
- Widespread availability of non-steroidal anti-inflammatory drugs (NSAIDs) contributes to their frequent use.
Purpose of the Study:
- To investigate the potential role of NSAIDs in the deterioration of varicella patients.
- To highlight the need for increased awareness and caution regarding NSAID use in pediatric varicella cases.
Main Methods:
- Retrospective case review of three pediatric patients with varicella.
- Analysis of clinical outcomes associated with NSAID use.
Main Results:
- Three cases suggested a link between NSAID administration and worsened varicella outcomes.
- NSAIDs may predispose varicella patients to severe bacterial infections.
Conclusions:
- NSAID use in pediatric varicella patients warrants caution.
- Enhanced patient and healthcare provider education on NSAID risks is recommended.
- The benefit/risk balance of NSAIDs in this population requires careful consideration.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
377
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
377
01:29Drug Dosing: Infants and Children
804
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
804
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
750
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
750
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
337
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
337
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
482
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
482
01:14Myocarditis III: Medical Management
324
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
324